A three-drug regimen cleared HIV in infant primates. Human trials are next.

Roughly 120,000 babies are born with HIV each year, and the standard treatment is a lifetime of antiretroviral pills. Access to those pills is itself the constraint: HIV still kills about 600,000 people a year, mostly in places where adherence and supply are fragile. A study published this month in Nature Microbiology from Oregon Health & Science University points to a different path: a one-time, three-drug combination cleared the virus in infant nonhuman primates when given within roughly three days of exposure.

This is a preclinical result, not a clinical cure. The team at OHSU's Oregon National Primate Research Center, working with the California National Primate Research Center, treated newborn macaques with a regimen that combined three things that had each failed on their own: broadly neutralizing antibodies (lab-made proteins that grab the virus and flag it for the immune system), standard antiretroviral therapy, and leronlimab, an experimental monoclonal antibody that blocks the CCR5 co-receptor HIV uses to enter cells. The three are delivered together, in the narrow window before the virus establishes the latent reservoir, the hidden stock of infected cells that current therapy controls but never erases.

Leronlimab, developed at OHSU, is in human trials but is not approved for HIV. The broadly neutralizing antibodies are also in human studies. Standard antiretrovirals are the global standard of care but require lifelong adherence and access. None of the three, used alone, has cleared HIV in this model. The OHSU team's claim is that the combination, at the right moment, does.

The co-lead authors, Jonah Sacha and Nancy Haigwood, treat the result as a research-direction step, not a clinical one. Sacha said the team was "astounded and overjoyed" by the primate data. The OHSU press release goes further: Sacha said the work "could go to clinical trials immediately." That statement is intent, not validation. The first human test, the team says, will most likely be in newly exposed adults, not newborns, and will need its own safety and dosing work.

Macaque anatomy resembles but is not identical to human infant biology. The three-day window assumes known exposure; in real-world delivery rooms, maternal status is often unknown, untreated, or detected too late. The number of animals, the durability of the viral clearance, and the exact dosing schedule are details the release does not pin down, and the underlying Nature Microbiology paper is the place to settle them. The Medical Xpress and news-medical.net coverage of the study reproduces the same claims without adding new data.

The first reading will come from human trials in newly exposed adults, which will test whether a three-mechanism hit during the early exposure window can convert HIV from a lifelong condition into a curable one in people.